Human tumor antigens recognized by T lymphocytes: Implications for cancer therapy

Rong Fu Wang, Steven A. Rosenberg

Research output: Contribution to journalArticle

Abstract

The adoptive transfer of cytotoxic T lymphocytes (CTLs) derived from tumor-infiltrating lymphocytes (TIL) along with interleukin-2 (IL-2) into autologous patients with cancer resulted in the objective regression of tumor, indicating that these CTLs recognized cancer rejection antigens on tumor cells. In the past year, a number of such tumor antigens were isolated by the use of cDNA expression systems and biochemical approaches. The majority of tumor antigens identified to date have been found to be nonmutated, self proteins. This raises important questions regarding the mechanism of antitumor activity and autoimmune disease. Several tumor-specific mutated tumor antigens have also been recently identified, which include cell cyclin-dependent kinase 4 (CDK4) and β-catenin. For the first time, a novel human cancer antigen was recently found to be generated by the use of an alternative open reading frame of the previously identified tyrosinase-related protein-1 (TRP-1) gene. The identification of human tumor rejection antigens provides new opportunities for the development of therapeutic strategies against cancer. The potential clinical applications of these tumor antigens will be discussed.

Original languageEnglish (US)
Pages (from-to)296-309
Number of pages14
JournalJournal of Leukocyte Biology
Volume60
Issue number3
StatePublished - Sep 1996
Externally publishedYes

Fingerprint

Neoplasm Antigens
T-Lymphocytes
Neoplasms
Cytotoxic T-Lymphocytes
Therapeutics
Cyclin-Dependent Kinase 4
Tumor-Infiltrating Lymphocytes
Catenins
Forensic Anthropology
Adoptive Transfer
Open Reading Frames
Autoimmune Diseases
Interleukin-2
Complementary DNA
Antigens
Genes
Proteins

Keywords

  • β-catenin
  • Autoimmune disease
  • Cyclin-dependent kinase 4
  • Interleukin-2

ASJC Scopus subject areas

  • Cell Biology

Cite this

Human tumor antigens recognized by T lymphocytes : Implications for cancer therapy. / Wang, Rong Fu; Rosenberg, Steven A.

In: Journal of Leukocyte Biology, Vol. 60, No. 3, 09.1996, p. 296-309.

Research output: Contribution to journalArticle

Wang, Rong Fu ; Rosenberg, Steven A. / Human tumor antigens recognized by T lymphocytes : Implications for cancer therapy. In: Journal of Leukocyte Biology. 1996 ; Vol. 60, No. 3. pp. 296-309.
@article{3258bf72855b485094b69c7210cbc754,
title = "Human tumor antigens recognized by T lymphocytes: Implications for cancer therapy",
abstract = "The adoptive transfer of cytotoxic T lymphocytes (CTLs) derived from tumor-infiltrating lymphocytes (TIL) along with interleukin-2 (IL-2) into autologous patients with cancer resulted in the objective regression of tumor, indicating that these CTLs recognized cancer rejection antigens on tumor cells. In the past year, a number of such tumor antigens were isolated by the use of cDNA expression systems and biochemical approaches. The majority of tumor antigens identified to date have been found to be nonmutated, self proteins. This raises important questions regarding the mechanism of antitumor activity and autoimmune disease. Several tumor-specific mutated tumor antigens have also been recently identified, which include cell cyclin-dependent kinase 4 (CDK4) and β-catenin. For the first time, a novel human cancer antigen was recently found to be generated by the use of an alternative open reading frame of the previously identified tyrosinase-related protein-1 (TRP-1) gene. The identification of human tumor rejection antigens provides new opportunities for the development of therapeutic strategies against cancer. The potential clinical applications of these tumor antigens will be discussed.",
keywords = "β-catenin, Autoimmune disease, Cyclin-dependent kinase 4, Interleukin-2",
author = "Wang, {Rong Fu} and Rosenberg, {Steven A.}",
year = "1996",
month = "9",
language = "English (US)",
volume = "60",
pages = "296--309",
journal = "Journal of Leukocyte Biology",
issn = "0741-5400",
publisher = "FASEB",
number = "3",

}

TY - JOUR

T1 - Human tumor antigens recognized by T lymphocytes

T2 - Implications for cancer therapy

AU - Wang, Rong Fu

AU - Rosenberg, Steven A.

PY - 1996/9

Y1 - 1996/9

N2 - The adoptive transfer of cytotoxic T lymphocytes (CTLs) derived from tumor-infiltrating lymphocytes (TIL) along with interleukin-2 (IL-2) into autologous patients with cancer resulted in the objective regression of tumor, indicating that these CTLs recognized cancer rejection antigens on tumor cells. In the past year, a number of such tumor antigens were isolated by the use of cDNA expression systems and biochemical approaches. The majority of tumor antigens identified to date have been found to be nonmutated, self proteins. This raises important questions regarding the mechanism of antitumor activity and autoimmune disease. Several tumor-specific mutated tumor antigens have also been recently identified, which include cell cyclin-dependent kinase 4 (CDK4) and β-catenin. For the first time, a novel human cancer antigen was recently found to be generated by the use of an alternative open reading frame of the previously identified tyrosinase-related protein-1 (TRP-1) gene. The identification of human tumor rejection antigens provides new opportunities for the development of therapeutic strategies against cancer. The potential clinical applications of these tumor antigens will be discussed.

AB - The adoptive transfer of cytotoxic T lymphocytes (CTLs) derived from tumor-infiltrating lymphocytes (TIL) along with interleukin-2 (IL-2) into autologous patients with cancer resulted in the objective regression of tumor, indicating that these CTLs recognized cancer rejection antigens on tumor cells. In the past year, a number of such tumor antigens were isolated by the use of cDNA expression systems and biochemical approaches. The majority of tumor antigens identified to date have been found to be nonmutated, self proteins. This raises important questions regarding the mechanism of antitumor activity and autoimmune disease. Several tumor-specific mutated tumor antigens have also been recently identified, which include cell cyclin-dependent kinase 4 (CDK4) and β-catenin. For the first time, a novel human cancer antigen was recently found to be generated by the use of an alternative open reading frame of the previously identified tyrosinase-related protein-1 (TRP-1) gene. The identification of human tumor rejection antigens provides new opportunities for the development of therapeutic strategies against cancer. The potential clinical applications of these tumor antigens will be discussed.

KW - β-catenin

KW - Autoimmune disease

KW - Cyclin-dependent kinase 4

KW - Interleukin-2

UR - http://www.scopus.com/inward/record.url?scp=0029814705&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029814705&partnerID=8YFLogxK

M3 - Article

C2 - 8830785

AN - SCOPUS:0029814705

VL - 60

SP - 296

EP - 309

JO - Journal of Leukocyte Biology

JF - Journal of Leukocyte Biology

SN - 0741-5400

IS - 3

ER -